It’s reported that mutations in the type II steroid 5 alpha-reductase (SRD5A2) gene, which replaces valine with leucine at codon 89, reduced the risk of prostate cancer in Italian patients (54). This evidence concerns the gene SRD5A2 and prostate cancer.